Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
3
×
detroit blog main
detroit top stories
immunotherapy
3
×
indiana blog main
indiana top stories
life sciences
merck
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
cancer
cell therapy
clinical trials
diagnostics
johnson & johnson
medicare
nivolumab
novartis
pembrolizumab keytruda
What
bio
roundup
3
×
drug
new
advantages
approval
bar
biogen’s
biopharma
biopharmaceutical
brings
car
celgene
colleagues
companies
convo
earlier
exome
expect
failures
gamble
government
health
hundreds
industry
littered
market
medco’s
medicine
mover
nash
news
patients
payers
physicians
plan
policy
price
pricing
published
Language
unset
Current search:
immunotherapy
×
roundup
×
" bristol-myers squibb "
×
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More